The Coronavirus pandemic might be over very soon. Researchers from Oxford University claim to have finally made a vaccine for the deadly Coronavirus. Till now no vaccine had a mass human trial permission, but Sarah Gilbert, professor of vaccinology at Oxford, has finally got it. She aims to use the trial vaccine on at least 500 volunteers by mid-may.
The vaccine trial has a few sets of rules. Adolescent adults and adults in the age group of 18-55 are being considered for the early and mid-stage random clinical trials. But this does not mean older people are left out.
It is because Coronavirus normally affects seniors more adversely. So the older individuals will receive it in phase 3 of the trial. Phase 3 of the immunization trial will take place only after phase 2 becomes successful. The phase 3 action plan involves administering the trial to almost 5000 individuals.
Oxford group in highly reputable Jenner Institute led by Sarah Gilbert (worked on Ebola, Flu and MERS) optimistic that vaccine for COVID19 will be ready by September.https://t.co/cMTp900ui0
— Luke O'Neill (@laoneill111) April 11, 2020
What is the principle behind this vaccine?
If everything goes according to the plan, the vaccine can then be pushed for mass production. Phase 3 of the clinical trial will give a better view of the effectiveness of the vaccine. Gilbert says, ” These predicted time frames will change according to ongoing cases rate. ” Gilbert has currently received $2.8 million from the National Institute for Health Research and the United Kingdom Research and Innovation in March to carry out clinical experiments for finding a cure for the Coronavirus.
According to Prof Sarah Gilbert a leading researcher from Oxford,a Vaccine for #COVID19 will take a min of 6 months to develop or “at best 12 to 18 months”:This should be our realistic guide as to the possible length of time to experience & endure this temporary inconveniences.
— Senator Shehu Sani (@ShehuSani) April 12, 2020
This research will determine the efficiency, immunization power, and safety of the clinical trial. The ChAdOx1 nCoV-19 is a vaccine against any kind of meningococcal disease. It will work as a placebo for control experiment purposes.
The ChAdOx1 nCoV-19 is a trial viral vector coming from a recombinant and harmless viral DNA. It is basically an adenovirus that has been altered to produce the ACE2 enzyme. It is the spike protein of the pandemic causing the SARS-CoV-2 virus.
Do you have any more questions about this new vaccine trial? Please let us know in the comments below.